PT  - JOURNAL ARTICLE
AU  - Li, Qilin
AU  - Ding, Xiuli
AU  - Xia, Geqing
AU  - Geng, Zhi
AU  - Chen, Fenghua
AU  - Wang, Lin
AU  - Wang, Zheng
TI  - A simple laboratory parameter facilitates early identification of COVID-19 patients
AID  - 10.1101/2020.02.13.20022830
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.13.20022830
4099  - http://medrxiv.org/content/early/2020/02/17/2020.02.13.20022830.short
4100  - http://medrxiv.org/content/early/2020/02/17/2020.02.13.20022830.full
AB  - The total number of COVID-19 patients since the outbreak of this infection in Wuhan, China has reached 40000 and are still growing. To facilitate triage or identification of the large number of COVID-19 patients from other patients with similar symptoms in designated fever clinics, we set to identify a practical marker that could be conveniently utilized by first-line health-care workers in clinics. To do so, we performed a case-control study by analyzing clinical and laboratory findings between PCR-confirmed SARS-CoV-2 positive patients (n=52) and SARS-CoV-2 negative patients (n=53). The patients in two cohorts all had similar symptoms, mainly fever and respiratory symptoms. The rates of patients with leukocyte counts (normal or decreased number) or lymphopenia (two parameters suggested by current National and WHO COVID-19 guidelines) had no differences between these two cohorts, while the rate of eosinopenia (decreased number of eosinophils) in SARS-CoV-2 positive patients (79%) was much higher than that in SARS-CoV-2 negative patients (36%). When the symptoms were combined with eosinopenia, this combination led to a diagnosis sensitivity and specificity of 79% and 64%, respectively, much higher than 48% and 53% when symptoms were combined with leukocyte counts (normal or decreased number) and/ or lymphopenia. Thus, our analysis reveals that eosinopenia may be a potentially more reliable laboratory predictor for SARS-CoV-2 infection than leukocyte counts and lymphopenia recommended by the current guidelines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China and the Major Scientific and Technological Innovation Projects of Hubei Province.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred to in this manuscript are available upon appropriate requests.